What Clinical Strategies Are Applied for Botulinum Toxin Injection in the Oromandibular Region? by Bakke, Merete et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
What Clinical Strategies Are Applied for Botulinum Toxin Injection in the
Oromandibular Region?
Bakke, Merete; Dalager, Torben; Møller, Eigild
Published in:
Botulinum Toxin Therapy Manual for Dystonia and Spasticity
DOI:
10.5772/64271
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
Unspecified
Citation for published version (APA):
Bakke, M., Dalager, T., & Møller, E. (2016). What Clinical Strategies Are Applied for Botulinum Toxin Injection in
the Oromandibular Region? In R. Rosales, & D. Dressler (Eds.), Botulinum Toxin Therapy Manual for Dystonia
and Spasticity (pp. 79-95). Rijeka: InTechOpen. https://doi.org/10.5772/64271
Download date: 03. Feb. 2020
2,850+
OPEN ACCESS BOOKS
98,000+
INTERNATIONAL
AUTHORS AND EDITORS 91+ MILLIONDOWNLOADS
BOOKS
DELIVERED TO
151 COUNTRIES
AUTHORS AMONG
TOP 1%
MOST CITED SCIENTIST
12.2%
AUTHORS AND EDITORS
FROM TOP 500 UNIVERSITIES
Selection of  our books indexed in the
Book Citation Index in Web of  Science™
Core Collection (BKCI)
Chapter from the book Botulinum Toxin Therapy Manual for Dystonia and Spasticity
Downloaded from: http://www.intechopen.com/books/botulinum-toxin-therapy-
manual-for-dystonia-and-spasticity
PUBLISHED BY
World's largest Science,
Technology & Medicine 
Open Access book publisher
Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Chapter 7
What Clinical Strategies are Applied for Botulinum
Toxin Injection in the Oromandibular Region?
Merete Bakke, Torben Dalager and Eigild Møller
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64271
Provisional chapter
What Clinical Strategies are Applied for Botulinum Toxin
Injection in the Oromandibular Region?
Merete Bakke, Torben Dalager and Eigild Møller
Additional information is available at the end of the chapter
Abstract
Botulinum neurotoxin (BoNT) inhibits the release of acetylcholine from cholinergic
nerve terminals in muscles or salivary glands. With reduced activation, the muscle
activity or secretion decreases. Indications for medical, non‐cosmetic use of BoNT in the
orofacial  area  include  among  others  oromandibular  dystonia,  painful  masseter
hypertrophy, Frey's syndrome, and severe drooling. The chapter covers anamnestic
characteristics of these conditions as well as clinical, electromyographic (EMG) and
laboratory findings,  treatment  methods with guided injections,  and outcome from
systematic treatment controls and follow‐up examinations.
Keywords: dystonia, drooling, Frey's syndrome, masticatory muscles, salivary glands
1. Introduction
There are a limited number of publications concerning botulinum neurotoxin (BoNT) treatment
in the oromandibular region, probably due to an overlap between the working areas for dentists
and  medical  specialists.  This  chapter  presents  various  neurological  and  neuromuscular
conditions that may benefit from treatment with BoNT, and strategies developed for such
treatment based on the collaboration between dental, neurological, and neurophysiological
specialists in hospitals and university clinics.
In addition to its action at cholinergic motor endings, acetylcholine is also an important
neurotransmitter in the autonomic nervous system. Thus, BoNT can be injected into muscles
and salivary glands to achieve therapeutic benefit in a large range of clinical conditions in the
oromandibular region such as dystonia, spasticity, and drooling. With reduced or blocked
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release of acetylcholine, the signals from the nervous system to the muscles or glands are
decreased. This results in a temporary functional denervation of the muscle fibers with
inhibition of the contractions and paralysis, and a temporary functional denervation of the
salivary glands with reduced secretion. In the oromandibular region with small muscle groups,
vital functions, and delicate anatomical structures, precise injection of the BoNT is crucial.
Diffusion at injection site and spread to unintended areas may lead to significant although
temporary discomfort. Such problems are most often swallowing difficulties due to effect on
adjacent muscle groups or dry mouth from displacement into salivary glands. Therefore, it is
strongly advocated to use guidance of the injections by EMG and/or ultrasonography to avoid
off‐target side effects and to secure effective placing of BoNT.
The latency for the full effect on the muscles after injection of BoNT is about a week, and the
effect is optimal within the first 1.5–2 months. Since neuromuscular transmission regenerates
slowly, muscle function is restored and the effect ceased after 3–6 months. Therefore, BoNT
treatments are typically repeated up to three to four times per year. Inhibition of the release of
acetylcholine from the postganglionic parasympathetic nerve ending to the salivary glands
and the effect on the salivary secretions has a similar course [1, 2, 21]. BoNT/A, onabotuli‐
numtoxinA (A/Ona), abobotulinumtoxinA (A/Abo), incobotulinumtoxinA (A/Inco), and
BoNT/B, rimabotulinumtoxinB (B/Rima) are used for the treatment of muscles and salivary
glands. There may be a small risk of developing antibodies and immunity by repeated
treatments with the same type of BoNT. Therefore, it is generally recommended to have an
interval of at least 3 months between treatments. If the patient seems to develop resistance to
one type of BoNT, so that treatment is ineffective, the other is attempted [1].
Unlike other drugs, there is no direct correlation between the dosage units for the various
compositions of BoNT. Depending on the preparation, there may be up to 50‐fold difference
in the number of units for the same treatment. Thus, the recommended dose is specific to the
individual preparations. Storage and dilution differ also for the different compositions.
Therefore, instructions for each preparation must be reviewed carefully to avoid mistakes, and
the substance for injection must be diluted with saline corresponding to the needed units and
the target for the treatment.
2. Oromandibular muscles
BoNT/A is the preferred choice for the muscles in the oromandibular region [3]. In most cases,
the indication for such treatment is based on electromyographic (EMG) examination with
bipolar surface electrodes and/or concentric needle electrodes. The indication for treating a
muscle is abnormally increased spontaneous activity. This is defined partly as a mean level
significantly above the reference for postural activity and partly as an activity pattern with
more than 100 turns per second [4]. The dose depends on the activity and volume of the
muscles (Figure 1) [1, 5–7]. When treating a muscle in a patient for the first time, the dose is
usually low. In the following treatments, it is adjusted individually corresponding to the effect.
This strategy not only reduces the possibility of side effects but also minimizes the cost.
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Figure 1. Oromandibular muscles, their maximal activation, and recommended doses of BoNT/A. Units are shown for
one muscle in one side and for the orbicularis oris muscle for each side of the upper and lower part of the lip. It is
advisable to start treatment with a low dose when treating a muscle in a patient for the first time. The patient should
be informed that injections into the digastric muscle may give temporary swallowing difficulties. A/Ona: onabotuli‐
numtoxinA and A/Inco: incobotulinumtoxinA. For A/Abo (abobotulinumtoxinA) is the dose probably 2.5 times  
higher [7].
The BoNT is injected as a bolus with cannulated electrodes and EMG guidance. One injection
site is normally sufficient in the oromandibular muscles. If unfamiliar with the possible
injection site in the oromandibular muscles, the procedures become easier after checking the
locations and anatomic details of the targeted muscles, and if possible, to palpate them during
maximal voluntary contraction (see Figure 1).
The site for the percutaneous injection into the masseter is the lower half of the superficial part,
for the anterior voluminous part of the temporalis muscle, for the medial pterygoid muscle on
the medial side of the ramus above its fusion with the masseter to form a common tendinous
sling, and for the anterior belly of the digastric muscle. With respect to the orbicularis oris
muscles, the injections are placed in the protruding parts but just above (upper lip) or below
(lower lip) the carmine margin of the lip. The lateral (external) pterygoid is best approached
intraorally to have direct access for palpation and injection. The direction of the needle
insertion is posteriorly and slightly laterally in parallel with the buccal surfaces of the maxillary
molars. Sometimes a more problematic percutaneous approach for the lateral pterygoid
muscle is used with injection in front of the tragus and the mandibular condyle. However, with
the intraoral approach, there is less vasculature encountered, and the risk of injecting several
branches of the trigeminal and facial nerves is reduced, as well as injecting the parotid gland
(that may lead to mouth dryness) [8]. In addition, the intraoral approach allows recording
during chewing as well as opening and lateral movements of the mandible [9]; (Figure 1).
When the cannulated electrode is inserted, the position is verified by the presence of well‐
defined sharp spikes with high EMG amplitude during posture. Subsequently, the level of
maximal activity is recorded to ascertain a normal interference pattern during maximal effort
of the muscle, that is, strong biting, jaw opening, lateral jaw movement, or pursing of the lips.
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2.1. Temporomandibular disorders (TMD)
As TMDs are the most common disorders in the oromandibular region, they should be
mentioned shortly. The prevalence in the adult population is 8–15% [10]. TMD are recognized
as a group of musculoskeletal and neuromuscular conditions that involve the temporoman‐
dibular joints, the masticatory muscles, and associated tissues [11]. The signs and symptoms
of TMD are orofacial pain and impaired jaw function, and they may be confused with other
conditions in the orofacial region. However, in contrast to the other conditions mentioned in
this chapter, BoNT treatment does not seem to have a significant role in the treatment of TMD
and episodic tension headaches, and evidence on the effect of BoNT on most orofacial pain
conditions is lacking [12, 13].
2.2. Painful bilateral masseter hypertrophy
Benign masseter hypertrophy is characterized by a soft swelling near the angle of the mandible.
It is relatively uncommon and may occur unilaterally or bilaterally [14].The swelling can be so
prominent that it is considered cosmetically disfiguring. Occasionally, there are also pain
symptoms. The condition may be associated with clenching and bruxism but often it is
idiopathic. Diagnosis of masseter hypertrophy should not be based on the clinical findings
alone as differential diagnoses are conditions such as tumors in the muscle and parotid gland.
The diagnosis should be supported by imaging with ultrasonic or magnetic resonance
scanning. Various treatment options have been reported including surgical reduction, while
injection of BoNT/A into the masseter muscle represents a less invasive modality [15, 16].
Figure 2. Increased bite force in a young man with painful masseter hypertrophy. Recording of maximum unilateral
clenching force during 1–2 s biting on a strain‐gauge transducer in the right and left molar region before treatment
with indications of reference values (M and SD; average of stored peak values) [17].
To illustrate the treatment strategy with BoNT for this condition, a case with a 24‐year‐old male
student is presented. He developed increasing masseter hypertrophy through some years with
high mental stress. The condition was painful and associated with a feeling of jaw tension. In
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addition, he reported sleep bruxism. The hypertrophy was documented by ultrasonic scanning
of the muscle structure. Examinations of the muscle function with bite‐force measurements
and EMG of the masseter muscles showed increased values (Figure 2). The increased muscle
volume was ascribed to his sleep bruxism, based on reports from his companions, and as the
dental attrition was greater than might be expected from his age. Treatment was performed
with BoNT/A injections into the masseter muscles. At the first treatment, the dose was low, 20
units A/Ona in each masseter. The intramuscular injections were repeated twice with 3–4
months intervals with 30 units A/Ona in each masseter to a total of three treatment series. No
further BoNT treatment was necessary as the pain and the thickness of the muscles were
reduced (Figure 3A and B). After the BoNT treatments, a bite splint was provided to reduce
further dental attrition as he still had episodes with grinding of his teeth during sleep.
Figure 3. Jaw pain and muscle activity in a young man with painful masseter hypertrophy treated with intramuscular
BoNT injection. (A) Jaw pain and feelings of jaw tension recorded on horizontal visual analog scales (VAS) before treat‐
ment and at controls during the treatment period. (B) Recordings with surface electromyography from right and left
masseter muscles during maximum biting in the intercuspal position measured before treatment and at controls dur‐
ing the treatment period. Reference value is M: 250 µV, SD: 180 µV (bipolar electrodes, mean voltage; custom‐designed
8‐channel EMG system; Electromyographic Laboratory, Dept. of Odontology, University of Copenhagen) [18].
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2.3. Oromandibular dystonia (OMD)
OMD is a rare focal neurological disorder affecting the lower part of the face and jaws. It is
characterized by sustained or repetitive involuntary jaw and tongue movements and facial
grimacing, caused by involuntary activity of the masticatory, facial, pharyngeal, lingual, and
lip muscles [19]. The dystonic activity may look similar to idiopathic sleep bruxism but it
usually ceases during sleep. Dystonia is thought to be derived from dysfunction of the basal
ganglia, and the excess movements to be due to loss of inhibitory motor control. Neurophy‐
siologic and neuroimaging studies have shown abnormalities at cortical and subcortical levels,
probably reflecting a dysfunction in the basal ganglia‐thalamo‐cortical circuits. However,
peripheral mechanisms and abnormal sensorimotor integration or somatosensory dysfunction
may occur in dystonia and aggravate the disorder [20].
OMD is typically classified as jaw opening, jaw closing, jaw deviating, or lingual dystonia
(tongue protrusion or curling) or combinations of these [8]. The combination of OMD,
blepharospasms (sustained, forced, involuntary closing of the eyelids), and dystonic move‐
ments of the upper face is known as Meige's syndrome [6]. OMD often interferes with normal
orofacial function, such as chewing and control of food bolus, swallowing, and verbal and
nonverbal communication. EMG recordings have shown high spontaneous and deviating
masticatory muscle activity with co‐contractions of antagonists and loss of rhythmicity during
chewing [5, 19]. Depending on the subtype, OMD may lead to trauma and damage of the
structures of the oral cavity, dental restorations, and dentures. Thus, jaw‐closing dystonia may
result in excessive dental wear, dental fractures, and trauma of the lips, gums, and tongue,
whereas jaw‐opening dystonia may be associated with temporomandibular joint overload and
dislocations. Consequently, there is need for both dental and neurological efforts as well as
collaboration between the two professions, although the diagnosis is neurological.
To illustrate the diversity of oromandibular dystonia and the need for careful control of BoNT
treatment, two patients are presented in the following section. First patient is a woman with
focal oromandibular dystonia and blepharospasms. She was referred for examination 15 years
earlier when she was 60 years. Her condition started 5 years previously in the eye region. Later
chewing and swallowing problems arose. In addition, constant and strong biting and grinding
movements developed, causing fractures of dental restorations and severe attrition of the teeth.
She used a bite splint but her dentition was also challenged by her drug‐induced hyposaliva‐
tion that contributed to increased caries activity and dental erosions. Besides clonazepam for
the dystonia, she was also medicated with psychoactive drugs and BoNT for the blepharo‐
spasms. She felt her dystonia as a severe handicap and therefore quit her job as secretary. Her
dystonia changed over the 15 years (Figure 4). It grew worse also including the lips.
The BoNT/A injections were adjusted accordingly and were able to reduce the high sponta‐
neous activity (Figure 5). In spite of the regular treatments, 3.3 BoNT series per year, the
dentition deteriorated and was reduced from consisting of a full complement of 29 with only
3 wisdom tooth missing, to 5 remaining natural tooth and prosthetic restorations (Figure 6).
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Figure 4. Shifts of dystonia types during a 15‐year period in an elderly woman.
Figure 5. Electromyographic recordings of spontaneous muscle activity in an elderly woman with oromandibular dys‐
tonia immediately before and after a BoNT treatment series. The activity is clearly reduced from the treatment, even in
the nontreated digastric muscles (bipolar surface electrodes, mean voltage; custom‐designed eight‐channel EMG sys‐
tem; Electromyographic Laboratory, Dept. of Odontology, University of Copenhagen).
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Fifteen years after the diagnosis, the dystonia was reduced compared to previous years. There
were fewer outbursts of dystonic activity and the involuntary jaw closing and lip dystonia was
less powerful. In spite of her tooth loss, the patient was satisfied with her dentures and her
chewing function had improved.
The second patient is a woman referred 17 years earlier when she was 59 years. She had
gradually developed an anterior mandibular overjet through some months and could only
with difficulty bite the teeth together with normal incisor relationships. There was no pain
associated with the condition, but increasing chewing and speech problems. She was diag‐
nosed with jaw deviation associated with dystonia of the lateral pterygoid muscle on both
sides.
Figure 6. Reduction in the number of teeth in an elderly woman during 15 years with oromandibular dystonia. The
deterioration of the dentition was associated with fractures of dental restorations and severe attrition of the teeth from
the dystonic jaw movements combined with increased caries activity and dental erosions from hyposalivation.
Her habitual occlusion was displaced 4–5 mm anteriorly to the normal sagittal relationship, a
so‐called mandibular overjet. However, analysis of the dental attrition on plaster models
revealed that the original occlusion in the front was a 2‐mm maxillary overjet, that is, a normal
sagittal relationship between the maxillary and mandibular anterior teeth. In contrast to the
patient with focal dystonia, the jaw deviation dystonia did not change over time. No other
muscles were involved. At first, treatment the lateral pterygoid muscles were injected with 20
units A/Ona each, and later on with 40 units each (Figure 7). The type of dystonia was
unchanged during 17 years in contrast to the female patient mentioned earlier. An excellent
treatment effect was obtained with complete reversal of the jaw protrusion and normalization
of chewing and speech, and it was repeated again and again with A/Ona injections on an
average 1.7 times per year (Figure 8).
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Figure 7. Electromyographic recordings of spontaneous muscle activity in an elderly woman with jaw deviation dysto‐
nia immediately before and after a BoNT treatment series. The injections in the lateral pterygoid muscles reduced the
activity in the treated muscles and normalized the dental occlusion (bipolar electrodes, mean voltage; custom‐designed
8‐channel EMG system; Electromyographic Laboratory, Dept. of Odontology, University of Copenhagen).
Figure 8. Unchanged jaw deviation dystonia persisting during a 17‐year period in an elderly woman.
2.4. Special conditions
Besides the already mentioned conditions, BoNT may be helpful in special situations as a
palliative intervention. Bite wounds in the tongue, lips, and cheeks may occur after accidental
or involuntary jaw closures in patients with cerebral palsy, parkinsonian syndromes, dementia,
or in retarded persons. Intramuscular injections with BoNT may attenuate bite force and thus
reduce the possibility of severe lesions. Frequent dislocations of the temporomandibular joints
represent a serious problem. They imply frequent contacts with the health care system and the
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emergency wards. Such habitual dislocations may result from neurological disorders, articular
hypermobility, or sequelae after jaw trauma. BoNT injections into the lateral pterygoid muscle,
in one or both sides, may reduce the problem if the situation is very frustrating and painful [21].
3. Drooling and secretory disorders of the salivary glands
Saliva secretion amounts to about 1 L per day with higher secretion rates during chewing and
taste stimulation than at rest [22]. Under normal physiological conditions, the resting secretion
rate of whole saliva is 0.2–0.5 ml per min during wakefulness and practically negligible during
sleep. The most important salivary glands are the parotid and the submandibular glands. They
have different functional patterns. Unstimulated the submandibular gland secretes the
majority of the saliva. In the stimulated state, the saliva production from the parotid and the
submandibular glands is approximately the same.
3.1. Drooling
Usually the saliva is swallowed unconsciously throughout the day. Unintentional loss of saliva
from the mouth, referred to as sialorrhoea or drooling, is most often due to decreased swal‐
lowing function rather than regular hypersalivation [23]. Drooling is unusual after the age of
5 years. In adults it is often related to gastroesophageal reflux, pregnancy, or develops as a side
effect of pharmacological treatment. Even patients with a low salivary flow rate may suffer
from sialorrhoea, when impaired swallowing function leads to accumulation of saliva in
mouth, and when insufficient lip closure or reduced oral sensitivity causes overflow and loss
of saliva from the mouth. If the saliva passes over the lower lip, it may run down the chin and
drip on the clothing, or it may be aspirated and cause coughing and lung inflammation. Thus,
drooling both results in reduced quality of life and poses a significant health risk.
Severe and psychosocially embarrassing drooling occurs especially in congenital or acquired
neurological disorders, such as parkinsonian syndromes, amyotrophic lateral sclerosis, and
cerebral palsy. Therefore, the general diagnosis and treatment of this type of drooling are
primarily within the working area for neurologists and takes place in a hospital setting.
However, dentists must be able to identify the problem in order to refer for treatment. The
treatment consists essentially in reducing the saliva secretion (Figure 9).
Such treatment may induce severe side effects in terms of dry mouth depending on its type,
which range from irreversible surgical interventions and radiation to reversible treatments
with intraglandular BoNT injections. As a consequence, the treatment may also cause accel‐
erated caries progression and other oral disorders. To minimize or prevent such development,
the patient should be followed closely by a dentist. However, as BoNT is one of the least
invasive treatments for drooling, it should always be considered as a relevant option. Based
on clinical evidence, treatment of severe drooling with percutaneous BoNT injections bilater‐
ally into the parotid and submandibular glands is considered useful [25].
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Figure 9. The effect of intraglandular injections into each parotid and submandibular gland with 15–40 units onabotuli‐
numtoxinA (A/Ona) or incobotulinumtoxinA (A/Inco) evaluated by visual analog scales (VAS) for drooling discomfort
and unstimulated whole saliva flow rate (ml/min × 100). Mean values before and 2 weeks after the treatment in 14 chil‐
dren with cerebral palsy and in 9 adults with amyotrophic lateral sclerosis and Parkinson's disease [2, 24].
Before the treatment start, it is important to record the frequency and extent of the drooling as
well as the impact of the drooling problem. The unstimulated salivary secretion rate should
be measured to clarify the cause and to determine the BoNT dose. Depending on the cooper‐
ation from the patient, saliva can be collected either in a cup by the draining method or by a
modified swab method with dental cotton rolls. Intraglandular injections with BoNT should
be given with ultrasonographic guidance to place the bolus centrally in the glands to ensure
maximum efficiency and minimize the side effects (Figure 10) [2, 24].
Light anesthesia or sedation may be necessary, especially in children, because the injections
are associated with local discomfort or pain and therefore provoke avert reaction and move‐
ments. Most clinical reports include treatments with commercially available preparations of
type BoNT/A, such as A/Ona and A/Inco, with 15–40 units in each parotid gland and in each
submandibular gland. Compositions of BoNT/B such as B/Rima in doses of 750–2500 units
have also been used for drooling, for example, Møller et al. [1]. The treatment effect of BoNT
is local. It has few side effects, which is usually short lasting and results from the injection
trauma. In few cases, there may be difficulty in swallowing due to impaired muscle activity
usually lasting some weeks. In all circumstances, the effect is temporary, and largely gone after
3 months. Repetition of the treatment and possible dose modifications should depend on the
effect of treatment, the current secretions rate, the drooling level, and the extent of any adverse
effects.
In children and young subjects, spontaneous cessation of drooling may occur as a result of the
physiological development [2]. Therefore, the drooling treatment should not be performed
automatically. It must be ensured that the drooling problems have returned after the expected
duration of the treatment effect before performing a new treatment. As a consequence, it is
advisable that treatment of drooling in these age groups is reversible, such as intraglandular
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injections with BoNT, as more invasive types of treatment with long‐term or permanent  
effect [2].
Figure 10. Ultrasonographic guidance during intraglandular injection of BoNT into the submandibular gland. The tip
of the injection needle is indicated by an arrow. (GE Logiq 9, “thyroid” settings; 12 MHz linear transducer).
3.2. Frey's syndrome
Frey’s syndrome or gustatory sweating in the preauricular area is an unpleasant phenomenon
typically appearing during meals. It may also be socially disabling when flushing and intense
sweating with subsequent wetting of clothes prevents the patient from eating in company. The
syndrome occurs after surgical procedures or traumas on the parotid gland. Frey's syndrome
is most likely caused by misdirected regeneration of cut or damaged parasympathetic fibers,
producing new ‘‘salivary’’ reflex arches activating sweat glands and small subcutaneous blood
vessels instead of salivary gland tissue. Thus, sweating and vasodilatation appear in the
reinnervated area when salivation is induced upon cholinergic stimulation from gustatory and
masticatory stimuli [26]. Intradermal injections of BoNT/A may be considered for gustatory
sweating and seems clinically effective [27]. It has also been suggested that Frey's syndrome
should be viewed as a dynamic process in which the stimulus for aberrant reinnervation of
parasympathetic nerve fibers can be reduced in some patients, with BoNT injections to the
treated areas [28]. Thus, the gustatory sweating may fade over time and does not necessarily
have to be retreated over and over again.
To localize the extent of involved skin area, Minor's iodine‐starch test is used before treatment.
An iodine solution (castor oil mixed with 2% iodine alcohol solution 1:9) is applied on the skin
of the involved cheek and dried for 0.5 min, and potato flour is spread out evenly and thinly
through a sieve over the area. During chewing of slices of apple, or sucking sour or strong‐
flavored candies for 5 min, a chemical reaction takes place between iodine and starch. This
leaves the zones of perspiration dark brown. Then the surplus of flour is gently removed by
compressed air and suction (Figure 11).
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Figure 11. Frey's syndrome or gustatory sweating after stabbing of the face in a 37‐year‐old woman. Dark brown spot‐
ted areas with perspiration obtained by the Minor's iodine‐starch test after eating apple.
Figure 12. Frey's syndrome or gustatory sweating after stabbing of the face in a 37‐year‐old woman. A: Self‐reported
impact of discomfort and problems with perspiration of the cheek in daily life on horizontal visual analog scales (VAS)
before treatment and at follow‐ups during 1 year after treatment. B: Self‐reported total score for severity and frequency
of gustatory sweating (0–7) before treatment and at follow‐ups during 1 year after treatment (modified after Thomas‐
Stonell and Greenberg [29]).
The distribution of the zones can be documented using a digital camera and by evaluating
the skin areas morphometrically [28]. The distribution of the dark brown spotted areas may
also be transferred to an acetate template with anatomical landmarks corresponding to ear,
eye, and mouth for reference during the injections [26]. Local anesthetic cream is applied to
the involved skin areas before BoNT treatment as the repeated intradermal injections may
be rather painful. The injections are made at 1‐cm distances, that is, one single injection per
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1 cm2, and for each injection, 0.5 units A/Ona or A/Inco is used [26]. After about 1 week, the
perspiration is reduced (Figure 12A and B), especially the severity. After treatment, not only
the sweating is reduced. The treated areas may also remain pale when the cheeks otherwise
blush during physical exercise or fitness. The effect may last for 0.5–1 year.
4. Conclusion
Several conditions in the oromandibular region may benefit from treatment with BoNT
injections. The treatment is local, and there are few side effects if the injections are guided by
electromyography and/or ultrasonography. However, animal studies indicate that changes in
muscle fibers and bone loss may be a risk factor for the use of BoNT in jaw muscles [30, 31]. In
any circumstances, the treatment should be planned by thorough examination of possible
injection targets, and the effect of the treatments must be controlled. The dose and targets
should not be repeated routinely but must be adjusted in repeated injection series based on
analysis of the effect. To get the best results and minimize or prevent side effects, collaboration
between doctors with several different professional backgrounds is important.
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